Abstracts tagged "Cell-signalling molecules"

Abstract Number: 1655 • ACR Convergence 2025
Aberrant Noncoding RNAs Are Enriched in Extracellular Vesicles and Implicated in Interferon Activation
Sandra Williams¹, Soyeong Sim² and Sandra Wolin², ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases; National Cancer Institute, Bethesda, MD, ²National Cancer Institute, Frederick, MD
Background/Purpose: Extracellular vesicles (EVs) are small structures that enclose a variety of nucleic acids. While much of the published work on EV RNA has focused…
Abstract Number: 0926 • ACR Convergence 2025
Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety
Minyun Zhou¹, Peng Gu², Mengyu Wang³, Yuxi Yan², Li Sun³, Yiling Chen³, Xin Wang³, Feng Tang¹, Shunwei Zhu² and Xiaofeng Zhao⁴, ¹State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing, ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic)
Background/Purpose: IRAK4 plays a pivotal role in the innate immune response by acting downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R), with both…
Abstract Number: 0921 • ACR Convergence 2025
Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling
Hannah Johnson¹, Wenxian Zhou², Michael Duryee¹, Carlos Hunter¹, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE
Background/Purpose: Citrulline (CIT) and malondialdehyde-acetaldehyde (MAA) co-adduct native proteins in RA tissues to create a dual pro-inflammatory and pro-fibrotic milieu. Our previous work demonstrated that…
Abstract Number: 0916 • ACR Convergence 2025
UVB-Irradiated Keratinocyte Extracellular Vesicles Trigger Innate Immune Activation via Type I Interferons and STING Pathway
Ahmed Eldaboush¹, Darae Kang² and Victoria Werth³, ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Potomac, MD, ³University of Pennsylvania, Wynnewood, PA
Background/Purpose: Extracellular vesicles (EVs) are cell-derived nanoparticles that mediate cell-cell communication. EVs are implicated in photosensitive autoimmune diseases like dermatomyositis (DM) and systemic lupus (SLE),…
Abstract Number: 0857 • ACR Convergence 2025
CD14-dependent MAP kinase signaling is required for pathogenic neutrophil extracellular trap formation in APS
Thalia Newman¹, NaveenKumar Somanathapura¹, Chao Liu², Srilakshmi Yalavarthi¹, Pooja Kapoor¹, Ajay Tambralli¹, Jacqueline Madison¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Superior Charter Twp, MI
Background/Purpose: Antibodies targeting beta-2-glycoprotein I (anti-β2GPI) promote inflammation and thrombosis in antiphospholipid syndrome (APS). It has been shown that anti-β2GPI activate neutrophils through Toll-like receptor…
Abstract Number: 0810 • ACR Convergence 2025
Spatial Transcriptomic-based Phenotyping of the Fibroblast Niches in Systemic Sclerosis-associated Primary Heart Involvement
Alexandru Micu¹, Alexandru-Emil Matei², Yi-Nan Li³, Ann-Christin Pecher⁴, Tim Filla⁵, Jörg Henes⁶, Markus Eckstein⁷, Karin Klingel⁸, Jörg Distler⁹ and Andrea-Hermina Györfi¹⁰, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ³University Hospital of Düsseldorf, Düsseldorf, Germany, ⁴Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁶Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ⁷Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁸Cardiopathology, Institute for Pathology, Eberhard-Karls-Universität Tübingen, Tübingen, Germany, ⁹University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹⁰Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc)-associated primary heart involvement (SSc-pHI) is one of the leading causes of mortality in SSc, yet its underlying cellular and molecular pathomechanisms…
Abstract Number: 0808 • ACR Convergence 2025
Spatial Transcriptomics Show Fibroblast LIF Receptor Drives Fibrosis in Systemic Sclerosis
Mari Kamiya¹, Hung Nguyen¹, Miles Tran², Ce Gao³, Sergio Poli¹, Yunju Jeong⁴, Louis Merriam⁵, Jinjun Shi⁶, Rachel Knipe⁷, Katharine Black⁸, Lida Hariri⁹, Carol Feghali-Bostwick¹⁰, Rodney Infante¹¹, Janelle Pugashetti¹², Justin Oldham¹², Ilya Korsunsky¹³, Kevin Wei¹⁴ and Edy Kim¹, ¹Division of Pulmonary and Critical Care Medicine, Department of Medicine (DOM), Brigham and Women's Hospital (BWH); Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Harvard Medical School, Boston, MA, ⁴Division of Pulmonary and Critical Care Medicine, Department of Medicine (DOM), Brigham and Women's Hospital (BWH), Harvard Medical School, Boston, MA, United States; Department of Food and Nutrition, College of Human Ecology, Kyung Hee University, Seoul, Republic of Korea, ⁵Division of Pulmonary and Critical Care Medicine, Department of Medicine (DOM), Brigham and Women's Hospital (BWH), Boston, MA, ⁶Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital (BWH); Harvard Medical School, Boston, MA, ⁷Division of Pulmonary and Critical Care Medicine, DOM, Massachusetts General Hospital; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital; Harvard Medical School, Boston, MA, ⁸Division of Pulmonary and Critical Care Medicine, DOM, Massachusetts General Hospital; Harvard Medical School, Boston, MA, ⁹Department of Pathology, Massachusetts General Hospital; Division of Pulmonary and Critical Care Medicine, DOM, Massachusetts General Hospital; Harvard Medical School, Boston, MA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Center for Human Nutrition, Dept. of Molecular Genetics, DOM, University of Texas Southwestern, Dallas, TX, ¹²Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, ¹³Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Division of Genetics, DOM, BWH; Harvard Medical School, Boston, MA, ¹⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune, fibroinflammatory disease of skin and visceral organs. Current SSc therapies have limited efficacy for progressive fibrosis. Our prior…
Abstract Number: 0797 • ACR Convergence 2025
Spatial transcriptomics identifies density-sensing fibroblasts in synovial lining
Sonia Presti¹, Kseniia Anufrieva², Ce Gao³, Sean Prell², Philip Blazar², Jeffrey Lange², Morgan Jones², Mihir Wechalekar⁴, Michael Brenner², Ilya Korsunsky⁵, Shideh Kazerounian² and Kevin Wei⁶, ¹Standford University, Stanford, ²Mass General Brigham, Boston, ³Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Harvard Medical School, Boston, MA, ⁴Flinders Medical Centre, Adelaide, Australia, ⁵Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Division of Genetics, DOM, BWH; Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: The synovial lining is crucial for joint homeostasis, forming a barrier and producing lubricants through specialized fibroblasts. These fibroblasts differ from sublining fibroblasts, which…
Abstract Number: 0020 • ACR Convergence 2025
Bulk RNA-sequencing of Leukocytoclastic Vasculitis Skin Biopsies Show Upregulation of Leukocyte Migration Genes
Anne Carlton, Lam Tsoi, Joseph Kirma, Jennifer Fox, Paul Harms and Johann Gudjonsson, University of Michigan, Ann Arbor, MI
Background/Purpose: Vasculitis encompasses multiple conditions united by end-organ damage due to an immune-mediated reaction against the vasculature. Leukocytoclastic vasculitis (LCV) is a subtype of cutaneous…
Abstract Number: 0586 • ACR Convergence 2025
Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis
Siba Raychaudhuri¹, Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Mather, CA, ³Sacramento VA Medical Center, Davis, CA
Background/Purpose: Check point inhibitor PD-1 (programmed death protein 1) is upregulated during T lymphocyte activation and is important for limiting the duration of activation. Thus,…
Abstract Number: 0038 • ACR Convergence 2024
The Role of Dual Specificity Phosphatase 22 (DUSP22) in Rheumatoid Arthritis: Mechanism and Genetic Investigations
Wei-Ting Hung¹, Yi-Ming Chen², Wen-Nan Huang³, Tsai-Hung Yen⁴, Tse-Hua Tan⁵ and Huai-Chia Chuang⁶, ¹Taichung Veteran General Hospital, Taichung City, Taiwan (Republic of China), ²Taichung Veterans General Hospital, Taiwan, Taichung, Taiwan (Republic of China), ³Taichung Veterans General Hospital, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ⁴Taichung Veterans General Hospital, Xitun District, Taichung City, Taiwan (Republic of China), ⁵National Health Research Institutes, Mao-Li, Taiwan (Republic of China), ⁶National Health Research Institutes, Zhunan, Taiwan (Republic of China)
Background/Purpose: Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. This study investigates the role of Dual Specificity Phosphatase…
Abstract Number: 0836 • ACR Convergence 2024
NF-κB Inducing Kinase Is a Therapeutic Target for Autoimmune Diseases by Orchestrating Both B Cell and T Follicular Helper Cell Responses
Jee Ho Lee¹, Manisha Mohandoss², Lichchavi Rajasinghe¹, Silvia Preite³, Katie Madore², Mark Birrell⁴, Jan Piet van Hamburg⁵, Sander Tas⁶, Matthew Perry³, Tatiana Ort¹ and Gary Sims¹, ¹Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaitherburg, ³Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁴Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, london, United Kingdom, ⁵Amsterdam UMC, Amsterdam, Netherlands, ⁶Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: T follicular helper (Tfh) cells are a specialized CD4+ T cell subset which can help B cells in the germinal center (GC) to drive…
Abstract Number: 0840 • ACR Convergence 2024
The Platelet Adenosinergic Axis as a Novel Therapeutic Target for Thrombotic APS
NaveenKumar Somanathapura K¹, Thalia Newman², Srilakshmi Yalavarthi¹, Bruna Mazetto Fonseca¹, Kaitlyn Sabb¹, Katarina Kmetova³, Emily Chong¹, Caroline Ranger¹, Cyrus Sarosh⁴, Jacqueline Madison¹, Ajay Tambralli¹, Jordan Schaefer¹, Michael Holinstat¹, Yu Zuo¹ and Jason Knight¹, ¹University of Michigan, Ann arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: How to most effectively inhibit antiphospholipid antibodies (aPL)-mediated platelet activation remains incompletely understood. CD73 is an ectoenzyme expressed on the platelet surface that generates…
Abstract Number: 0879 • ACR Convergence 2024
A Novel, Oral, Allosteric Inhibitor of Tyrosine Kinase 2 (TYK2) Demonstrates In Vitro Potency, Selectivity, and In Vivo Efficacy in Mouse Models of Psoriasis
Razika Hussein¹, Pamela Tsuruda¹, Shahab Mortezaei¹, Nicky Ferdyan¹, Christopher Wegerski², Karthik Srinivasan¹, Gavin Hirst¹ and Neelufar Mozaffarian¹, ¹Atomwise Inc., San Francisco, ²Atomwise Inc., San Francisco, CA
Background/Purpose: Tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family, plays a key role in several inflammatory diseases. Orthosteric, small molecule inhibitors…
Abstract Number: 0932 • ACR Convergence 2024
IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
Grace Teng¹, Thomas Fung², Annamaria Mocciaro², Ceyda Llapashtica¹, Angie Hammond³, Jesse Gurgel⁴, zhiyu Huang¹, Maria Mouchess¹, Vanessa Gorney⁵, Wesley Minto¹, Sunish Mohanan¹, Adam Schrier¹, Wylie Palmer², Alexandra Borodovsky² and Gundula Min-oo¹, ¹Gilead Sciences, Foster City, CA, ²Nurix Therapeutics, San Francisco, CA, ³Gilead Sciences, Inc., Seattle, WA, ⁴Gilead Sciences, Seattle, CA, ⁵Alterome Therapeutics, San Diego, CA
Background/Purpose: Despite advances in treatment, chronic inflammatory diseases such as rheumatoid arthritis (RA) represent areas of high unmet medical need. IRAK4 is a proximal mediator…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].